MedDataX Logo

Safety of Sofosbuvir ,Daclatasvir in HCV Patients and RAVS in Resistent and Relapsed Cases

NCT03572140 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 297

Last updated 2018-06-29

No results posted yet for this study

Summary

To identify side effects of Sofosbuvir/ Daclatasvir treatment regimen of chronic HCV GT-4 infection.

* To assess the occurrence and the prevalence of RAVs in patients with treatment failure and relapse after sofosbuvir and daclatasvir with assessment of their types .
* To examine the GT4 subtypes by phylogenetic analysis and baseline sequence variability among subtypes and their potential impact on treatment outcome and development of viral resistance in patients who received a regimen of Sofosbuvir/ Daclatasvir for treatment of chronic HCV GT-4.
* To assess the differences in patient demographics across GT4 subtypes.

Conditions

  • HCV

Interventions

DIAGNOSTIC_TEST

RAVS In relapsed and resistent cases

assessment of RAVS in relapsed and resistant cases after sofosbuvir plus daclatasvir regimen

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Principal Investigators

  • Ahlam Farghaly, Professor · Assiut University

  • haidi ramadan, Lecturer · Assiut University

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-07-01
Primary Completion
2020-07-01
Completion
2020-08-01

Related Clinical Trials

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03572140 on ClinicalTrials.gov